about
Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo.Excess visceral adiposity induces alterations in mitochondrial function and energy metabolism in esophageal adenocarcinoma.Lipoxygenase metabolism: roles in tumor progression and survival.Obesity and post-operative complications in patients undergoing non-bariatric surgery.Obesity and gastrointestinal cancer.Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention.The esophagitis to adenocarcinoma sequence; the role of inflammation.Could signal transducer and activator of transcription 3 be a therapeutic target in obesity-related gastrointestinal malignancy?The role of inflammation in cancer of the esophagus.Targeting T cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment.Influence of the metabolic syndrome on leptin and leptin receptor in breast cancer.Emerging Concepts Linking Obesity with the Hallmarks of Cancer.Elevated Tumor Expression of PAI-1 and SNAI2 in Obese Esophageal Adenocarcinoma Patients and Impact on Prognosis.The SGBS cell strain as a model for the in vitro study of obesity and cancer.MMP9 expression in oesophageal adenocarcinoma is upregulated with visceral obesity and is associated with poor tumour differentiation.Alterations in DNA repair efficiency are involved in the radioresistance of esophageal adenocarcinoma.Role of the insulin-like growth factor 1 axis and visceral adiposity in oesophageal adenocarcinoma.CCR1 antagonism attenuates T cell trafficking to omentum and liver in obesity-associated cancer.Reciprocal effects of Th1 and Treg cell inducing pathogen-associated immunomodulatory molecules on anti-tumor immunity.Impact of the inflammatory microenvironment on T-cell phenotype in the progression from reflux oesophagitis to Barrett oesophagus and oesophageal adenocarcinoma.Parallel Profiles of Inflammatory and Effector Memory T Cells in Visceral Fat and Liver of Obesity-Associated Cancer Patients.Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma.Impact of visceral obesity and metabolic syndrome on the postoperative immune, inflammatory, and endocrine response following surgery for esophageal adenocarcinoma.The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cells.IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity.Establishing computed tomography–defined visceral fat area thresholds for use in obesity-related cancer researchVisceral obesity, metabolic syndrome, insulin resistance and cancerPro-inflammatory and tumour proliferative properties of excess visceral adipose tissueT lymphocyte activation in visceral adipose tissue of patients with oesophageal adenocarcinomaHeat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccineAltered T Cell Migratory Capacity in the Progression from Barrett Oesophagus to Oesophageal Adenocarcinoma.The 'obesity paradox' in action with cancer immunotherapy
P50
Q34678587-60485FBE-B0B9-438E-9253-C132AB2F5FF7Q34695013-3DD36138-3D31-4762-A9CD-BF46352CEF5BQ36974347-CA3A514E-E470-4AAE-A779-5EF4A90D4DEAQ37660520-EDADA6A1-6805-43EF-8459-057B19558269Q37715885-59250245-8CF4-4AC1-885A-D8BE2EDDD41EQ37963769-FB3E232F-DE23-47B9-A281-3E72D1BBA8C1Q38133153-BD913ACD-6B39-468A-A927-EA5FA1874FC0Q38155819-0C4CAB50-A457-4215-9273-CF0625EA49A3Q38214324-B7B35DB4-288C-4C2E-8F68-B07317147BC9Q38218127-E323ABA9-7539-4A72-A7C1-CADA17944CF1Q38335161-10B6C524-2973-41C4-AE15-638E953A5A37Q38955429-E7A8DCDC-C94C-400C-98C0-CBB26DA9652AQ39226627-59B44338-4DFE-44F4-BD65-C29698705B9FQ39303927-9414A057-C008-4B52-BAC1-9E5718D47EA6Q39436498-329E5A0E-304D-4A1E-98E6-665BD81691E5Q39624319-2B7C3244-36B0-43FD-A0A8-F14F6C5AB9B7Q39664897-55551ADE-D1B3-4B15-A45A-0D3BC0A5AB24Q39862548-C7AA2B25-E876-4DDB-A586-3056A8C41BAEQ40174497-1EB96359-34B7-42D9-A9AF-2D531E478E60Q40372298-B11741D8-B6C0-4B62-8C86-5E74C4C59C86Q42096731-5F87364F-BC4C-45D0-86C1-D514236C4824Q50021256-E1AA61A9-B8AD-45D4-B160-2EFA136831BEQ51018386-41F4187F-CADB-4D9B-8153-7B6666C334C8Q53135213-4642C601-C4E2-40B0-BD1B-CC7127E5A93AQ54545081-61F03B3C-AE4C-4FFC-A9BC-F6321BB7485EQ57521537-AF18FCD0-6317-4DF7-8374-CEEA3B39356CQ57521562-A35A62D9-3E71-48FF-A9D2-4F9D9D723FA2Q57521566-0C921DFD-619C-40E0-B36F-05D2A66BFC8AQ57521578-0CE36F9A-9479-4C03-A004-5CFE6BA13C41Q59632110-CF9255F4-5B93-4448-9A59-2AA7486ADAC6Q64968702-D6C38EDD-5679-4BB1-8678-ECFA8B908398Q91168742-C9383537-81FC-422E-ACBA-538AB1ED6E41
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-3363-3763
@en
name
Joanne Lysaght
@ast
Joanne Lysaght
@en
Joanne Lysaght
@es
Joanne Lysaght
@nl
type
label
Joanne Lysaght
@ast
Joanne Lysaght
@en
Joanne Lysaght
@es
Joanne Lysaght
@nl
prefLabel
Joanne Lysaght
@ast
Joanne Lysaght
@en
Joanne Lysaght
@es
Joanne Lysaght
@nl
P106
P1153
6506351445
P21
P31
P496
0000-0003-3363-3763